Anika Therapeutics appointed Joseph Darling as CEO. Darling brings more than 20 years of experience in executive management and leadership. He previously served at Abbott Laboratories, Baxter Healthcare, Smith & Nephew, CONMED, and Wyeth-Ayerst.
Exogenesis Corporation named Dmitry Shashkov as president and CEO. Shashkov previously served as president and CEO of H.C. Stark Fabricated Products and in several roles at Honeywell Specialty Materials. Prior to Honeywell, he worked at McKinsey & Company, managing projects in chemical, pharmaceutical, and telecommunication industries. Exogenesis is commercializing NanoAccel, a technology that modifies materials at a nanoscale level. It has entered into commercialization agreements with Vallum Corporation to produce enhanced interbody devices for spine fusion procedures.